Statements on Improving Access to Medical Care

The Denka Group regards the issue of access to medical care as an important human rights issue. Many people, especially in developing countries, have difficulty receiving appropriate medical care due to weak medical infrastructure and environments with limited access to medical care. The spread of infectious diseases is particularly serious, and the lack of testing for diseases that can be cured by early diagnosis leads to a vicious cycle of further infection and loss of life for many people. Improving access to medical care will reduce the number of such people and protect the livelihoods and lives of people around the world. The Denka Group will continue to contribute to improving access to medical care for all people through its diagnostic agent and health care services business in order to achieve one of the Materiality items in our management plan, “Increasing healthy life expectancy and correcting health disparity.”

Initiatives in Developing Countries for Pharmaceutical Products

The Denka Group has provided the rapid Ebola virus antigen diagnostic kit, which was jointly developed with Professor Ayato Takada of Hokkaido University, to the Democratic Republic of Congo through JICA. These kits have been used for early testing during the country’s several Ebola outbreaks, helping to prevent the spread the disease. Since the kit takes approximately 10 minutes to determine a result, can be stored at room temperature, and does not require special equipment, it can be used in areas without infrastructure. Following the approval of its production and marketing in Japan by the Pharmaceuticals and Medical Devices Agency (PMDA) in 2021, it was officially licensed for use by the Democratic Republic of Congo’s National Institute of Biomedical Research in 2024. It is expected to contribute to the rapid diagnosis of future Ebola hemorrhagic fever and prevention of the spread of infection.

Proper Promotion Activities for Pharmaceutical Products

Denka complies with the Code of Practice formulated by the Japan Pharmaceutical Manufacturers Association (JPMA) and the In-Vitro Diagnostic Promotion Code of the Japan Association of Clinical Reagents Industries (JACRI). Denka is responsible for all promotional activities, including the actions of its medical representatives, and will establish an internal system for proper promotion and engage in responsible pharmaceutical product advertising and marketing.

• *Both prescription pharmaceutical products and in-vitro diagnostic products are hereinafter referred to as “pharmaceutical products.”

<Promotion Code for Prescription Pharmaceutical Products and In-Vitro Diagnostics, Section 1: Denka’s Responsibilities>

1. Appoint appropriate persons as medical representatives and continue to provide education and training.
2. Provide information on indications (purpose of use), dosage and method of use (method of operation), or sensitivity, accuracy, reproducibility (performance), correlation, etc. in a proper manner based on data with a clear scientific basis.
3. Accurately and promptly collect and communicate pharmaceutical information.
4. Establish an internal system to ensure that activities are conducted in compliance with relevant laws and regulations and voluntary regulations.

As a company that plays a role in medical care, Denka recognizes that printed promotional materials, advertisements in specialist magazines (print), presentation slides, and video recordings, and other audiovisual promotional materials are important means of providing pharmaceutical information in the course of implementing responsible pharmaceutical product information activities. In creating and using these materials, we will comply with the Pharmaceutical Affairs Law (Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices), the Guidelines on Information Provision in connection with Promotional Activities for Ethical Drugs, the Guidelines on Information Provision in connection with Promotional Activities for In-Vitro Diagnostic Drugs, the Guidelines for the Preparation of Product Information Brochure for Prescription Drugs, as well as our own Promotion Code, which conforms to these guidelines, and we will ensure that the content is scientifically based, accurate, fair, and objective